| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.3 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.3 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.3 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.3 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.058 | 0.3 |